gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VRDNHealthcarePharmaceuticals

Viridian Therapeutics, Inc. Common Stock (VRDN)

$29.06+15.53%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$29.05▲ 28.85% in range
Nov 4, 2025Low $13.30 · High $33.78Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Viridian Therapeutics closed at $29.05 on Nov 4, up 15.53%, 14.0% below its 52-week closing high. Volume of 11.2M shares was 5.09× its 20-day average (well above normal).

Split-adjusted performance: +59.5% over one month, +65.7% over six months, +25.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $284K, up 278.7% from a year earlier, with a net margin of -39726.8%.

Short interest was 18.0M shares at the Oct 15 settlement (18.5% of float, 8.0 days to cover).

Market cap$3.29B113.3M shares
Revenue · quarter$284.0K+278.7% YoY
Diluted EPS$-1.05—
P/E · TTM—P/S 46.3×
Net margin-39,726.8%Gross 100.0%
Dividend yieldNone
52-week range13.30 – 33.78−14.0% from high
Volume11.2M5.09× 20-day avg
Volatility · 60d55.5%Annualised
Short % of float18.5%8.0 days to cover
Net cash$625.7MCash $981.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +19.7%1M +59.5%3M +29.1%6M +65.7%YTD −6.6%1Y +25.5%3Y +123.2%5Y +62.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum96
Revenue growth92
Net margin2
Value (low P/E)—
Size86

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short18.0M+0.2% vs prior
Days to cover8.0Settled Oct 15
% of float18.5%
Short vol. 10d48.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VRDNViridian Therapeutics$29.06+15.53%+65.7%+278.7%−39726.8%—$3.29B
ELVNEnliven Therapeutics$47.25+5.40%+14.7%———$3.46BCompare
DYNDyne Therapeutics$18.54+2.71%−1.6%———$3.46BCompare
IDYAIDEAYA Biosciences$32.36+3.29%+12.6%−95.1%−1227.8%—$3.12BCompare
BHCBausch Health Companies$8.34+2.46%+47.6%+9.7%14.8%—$3.12BCompare
VKTXViking Therapeutics$27.97+7.21%−13.4%———$3.57BCompare
OGNOrganon &$13.83−0.14%+3.1%−1.7%10.4%17.1$3.63BCompare
AMLXAmylyx Pharmaceuticals$29.40+0.68%+83.1%———$3.69BCompare
IRONDisc Medicine$83.28+2.61%+21.3%———$3.70BCompare

News about Viridian Therapeutics

All news →
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionThe Motley Fool · May 17, 2026NeutralKopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should KnowThe Motley Fool · Apr 21, 2026▼ NegativeViridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire Inc. · Mar 31, 2026▼ Negative

Quick answers

What does Viridian Therapeutics do?
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED.
What is VRDN's market cap?
$3.29B, based on the Nov 4 close of $29.05.
Does Viridian Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VRDN is sold short?
18.0M shares, 18.5% of float, as of Oct 15, 2026.
What sector is VRDN in?
Healthcare, in the Pharmaceuticals industry.

About Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

HQ: Waltham, MA252 employeesListed Jun 18, 2014viridiantherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology